Sarepta Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Sarepta Therapeutics de 44.9% y 24.2% por año respectivamente. Se prevé que el BPA crezca en un 42.6% al año. Se espera que la rentabilidad financiera sea de 50.6% en 3 años.

Información clave

44.1%

Tasa de crecimiento de los beneficios

41.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.3%
Tasa de crecimiento de los ingresos	23.6%
Rentabilidad financiera futura	50.6%
Cobertura de analistas	Good
Última actualización	13 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02

Recent updates

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Jul 24

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Jul 05

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 17

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

May 08

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 05

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Apr 15

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 11

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 02

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Feb 06

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Jan 22

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jan 10

Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001

Sep 29

Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027

Sep 12

Sarepta says FDA lifted clinical hold on Duchenne candidate

Sep 06

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Aug 22

Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses

Aug 08

Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder

Jul 29

Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?

May 09

Sarepta: The DMD Leader

Apr 26

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:SRPT - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,854	1,504	1,367	1,589	11
12/31/2025	3,106	1,009	1,181	1,289	15
12/31/2024	1,737	130	-287	11	14
6/30/2024	1,505	47	-528	-396	N/A
3/31/2024	1,403	17	-552	-534	N/A
12/31/2023	1,243	-536	-486	-501	N/A
9/30/2023	1,105	-691	-512	-539	N/A
6/30/2023	1,003	-908	-432	-489	N/A
3/31/2023	976	-1,115	-470	-434	N/A
12/31/2022	933	-703	-358	-325	N/A
9/30/2022	876	-716	-289	-262	N/A
6/30/2022	835	-507	-348	-322	N/A
3/31/2022	766	-357	-285	-364	N/A
12/31/2021	702	-419	-382	-443	N/A
9/30/2021	646	-486	-551	-588	N/A
6/30/2021	600	-634	-681	-702	N/A
3/31/2021	573	-704	-795	-701	N/A
12/31/2020	540	-554	133	107	N/A
9/30/2020	495	-601	155	118	N/A
6/30/2020	450	-530	342	289	N/A
3/31/2020	407	-656	373	318	N/A
12/31/2019	381	-715	-516	-456	N/A
9/30/2019	365	-620	-478	-415	N/A
6/30/2019	345	-570	-536	-461	N/A
3/31/2019	323	-403	-567	-499	N/A
12/31/2018	301	-362	-450	-389	N/A
9/30/2018	274	-245	-345	-297	N/A
6/30/2018	241	-216	-277	-242	N/A
3/31/2018	203	-170	N/A	-210	N/A
12/31/2017	155	-51	N/A	-232	N/A
9/30/2017	103	-115	N/A	-282	N/A
6/30/2017	57	-124	N/A	-285	N/A
3/31/2017	22	-123	N/A	-243	N/A
12/31/2016	5	-267	N/A	-246	N/A
9/30/2016	1	-243	N/A	-196	N/A
6/30/2016	1	-239	N/A	-182	N/A
3/31/2016	1	-218	N/A	-167	N/A
12/31/2015	1	-220	N/A	-149	N/A
9/30/2015	0	-200	N/A	-144	N/A
6/30/2015	1	-177	N/A	-133	N/A
3/31/2015	4	-169	N/A	-144	N/A
12/31/2014	10	-136	N/A	-129	N/A
9/30/2014	12	-100	N/A	-121	N/A
6/30/2014	15	-113	N/A	-105	N/A
3/31/2014	16	-98	N/A	-78	N/A
12/31/2013	14	-112	N/A	-65	N/A
9/30/2013	19	-165	N/A	-54	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (44.9% al año) de SRPT es superior a la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que los beneficios (44.9% al año) de SRPT crezcan más rápidamente que el mercado US (15.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de SRPT crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (24.2% al año) de SRPT crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (24.2% al año) de SRPT crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de SRPT sea muy elevada dentro de 3 años (50.6%).

Sarepta Therapeutics Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 17%

Consensus revenue estimates fall by 12%

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

Price target increased by 12% to US$187

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Sarepta Therapeutics, Inc. Announces Appointment of Deirdre P. Connelly to Its Board of Directors

Executive VP & CFO recently sold US$822k worth of stock

Executive VP & CFO notifies of intention to sell stock

Consensus EPS estimates increase by 17%

Insider recently bought US$5.0m worth of stock

Consensus revenue estimates fall by 12%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2025

Sarepta Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%

Executive VP exercised options and sold US$2.3m worth of stock

Price target increased by 12% to US$187

Sarepta Therapeutics, Inc. Announces Expanded US FDA Approval of Eletidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Now 21% undervalued after recent price drop

Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear

Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Board Member notifies of intention to sell stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 8.0% to US$162

Sarepta Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth

Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval

Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate

Forecast to breakeven in 2024

There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues

Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?

Independent Chairwoman exercised options to buy US$1.2m worth of stock.

Independent Director recently bought US$3.9m worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 21% to US$143

Sarepta Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

No longer forecast to breakeven

Insider recently bought US$3.7m worth of stock

Consensus estimates of losses per share improve by 22%

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Board Member notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sarepta Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Sarepta Therapeutics, Inc. Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?

Consensus EPS estimates upgraded to US$3.68 loss

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 13%

Price target increased by 11% to US$167

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Independent Chairwoman exercised options to buy US$2.6m worth of stock.

Sarepta Therapeutics Announces That U.S. FDA Has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’S Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Insider recently sold US$94k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022